ASMBAssembly Biosciences, Inc.
Price
-4.4%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality strong, a flag to check, growth fading, the market undecided.
Charts
As reported to the SEC, without any scoring.
Assembly Biosciences, Inc. (ASMB) reported revenue of $13M in Q2 2026 (quarter ended Jun 30, 2026), up 39% from the same quarter a year earlier. That came with net loss of $3.9M. For the full year FY2025, revenue was $72M (+154% year on year) and net income −$6.1M. The next results filing is expected around Nov 9, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 14, 2026Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates.Earnings release · press release
- Aug 13, 2026Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates.Acquisition or disposition completed · press release
- Jun 5, 2026Amendment No. 3 to Amended and Restated 2018 Stock Incentive Plan At the Assembly Biosciences, Inc. (the "Company") Annual Meeting of Stockholders held on June 4, 2026, (the "Annual Meeting"), the Company's stockholders approved Amendment No. 3 ("Amendment No. 3") to the Assembly Biosciences, Inc. Amended and Restated …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.